secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allakos Inc. (—)
CIK:        0001564824
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0000950170-24-004686
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allakos halts lirentelimab after Phase 2 failures; cuts workforce 50%, extends cash runway to mid-2026
--------------------------------------------------------------------------------

- ATLAS and MAVERICK trials missed primary endpoints (EASI-75 and UAS7 change); lirentelimab development stopped.
- Workforce reduced by ~50%; total restructuring costs estimated at ~$30M (majority in H1 2024).
- Year-end 2023 cash, equivalents and investments ~$171M; 2024 net cash used in ops $85-90M.
- Cash runway extended into mid-2026; focus on AK006 Phase 1 program including CSU and healthy volunteer trials.
- Phase 1 AK006 SAD/MAD dosing to complete Q1 2024; CSU patient trial initiation Q2 2024; topline data year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1564824/000095017024004686/0000950170-24-004686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1564824/000095017024004686/allk-20240116.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-004686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer